Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Annji Pharmaceutical Co's interest expense for the
six
months ended in Dec. 2025 was NT$ -0.78 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.60 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Annji Pharmaceutical Co's Operating Income for the
six
months ended in Dec. 2025 was NT$ -191.50 Mil. Annji Pharmaceutical Co's Interest Expense for the
six
months ended in Dec. 2025 was NT$ -0.78 Mil.
Annji Pharmaceutical Co did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Annji Pharmaceutical Co (ROCO:7754) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Annji Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as
Annji Pharmaceutical Co did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Annji Pharmaceutical Co Interest Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annji Pharmaceutical Co Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Expense of NT$-1.60 Mil mean?
Annji Pharmaceutical Co (ROCO:7754) has a Interest Expense of NT$-1.60 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Annji Pharmaceutical Co and its competitors.
Is Annji Pharmaceutical Co's Interest Expense too high?
Annji Pharmaceutical Co's current Interest Expense is NT$-1.60 Mil. Overall, Annji Pharmaceutical Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's Interest Expense compare to VRTX and REGN?
Annji Pharmaceutical Co's Interest Expense of NT$-1.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Annji Pharmaceutical Co and its competitors. Annji Pharmaceutical Co's current Interest Expense is NT$-1.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current Interest Expense of NT$-1.60 Mil. The current Interest Expense is NT$-1.60 Mil. Annji Pharmaceutical Co's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current Interest Expense is NT$-1.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
10GF Score
Get the complete analysis for ROCO:7754
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7754 has been successfully added to your 
